Rentschler Biotechnologie has started operation of a 2,500 L multi-process production suite for its bio-CMO operations. The company now has nine stand-alone GMP suites with volumes of 30, 250, 500 and 2,500 liters, allowing the production of material for clinical trials as well as commercial supply.
The new bioreactor is designed such that batch, fed-batch, or perfusion cell culture processes can be run. Protein purification is performed in two suites for pre- and post-virus inactivation, respectively.
The global market for biopharmaceutical products is growing constantly and rapidly. As a consequence, since 2002, Rentschler Biotechnologie has invested more than 70 million Euros to enhance its production capacities, while tripling its workforce since 2001 to 350.
Magazine
